Clinical Trial Update: Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of JK07 for heart failure (reduced and preserved ejection fraction) with Group 2 pulmonary hypertension is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Heart Failure with Reduced Ejection Fraction
• Pulmonary Hypertension Group

Drugs mentioned

• JK07

Snippet

Sponsor: Salubris Biotherapeutics Inc | Conditions: HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: RECRUITING